Merck KGaA - Product Pipeline Review - 2016 Summary Global Markets Direct's, 'Merck KGaA - Product Pipeline Review - 2016', provides an overview of the Merck KGaA's pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Merck KGaA, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the pipeline therapeutic landscape of Merck KGaA - The report provides overview of Merck KGaA including its business description, key facts, and locations and subsidiaries - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report assesses Merck KGaA's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report features Merck KGaA's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects Reasons To Buy - Evaluate Merck KGaA's strategic position with total access to detailed information on its product pipeline - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Merck KGaA - Identify potential new clients or partners in the target demographic - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Merck KGaA's pipeline depth and focus of pipeline therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
Table of Contents
Table of Contents 2 List of Tables 7 List of Figures 7 Merck KGaA Snapshot 8 Merck KGaA Overview 8 Key Information 8 Key Facts 8 Merck KGaA - Research and Development Overview 9 Key Therapeutic Areas 9 Merck KGaA - Pipeline Review 14 Pipeline Products by Stage of Development 14 Pipeline Products - Monotherapy 15 Pipeline Products - Combination Treatment Modalities 16 Pipeline Products - Partnered Products 17 Partnered Products/Combination Treatment Modalities 18 Pipeline Products - Out-Licensed Products 20 Out-Licensed Products/Combination Treatment Modalities 21 Merck KGaA - Pipeline Products Glance 22 Merck KGaA - Late Stage Pipeline Products 22 Filing rejected/Withdrawn Products/Combination Treatment Modalities 22 Phase III Products/Combination Treatment Modalities 23 Merck KGaA - Clinical Stage Pipeline Products 24 Phase II Products/Combination Treatment Modalities 24 Phase I Products/Combination Treatment Modalities 25 Merck KGaA - Early Stage Pipeline Products 26 Preclinical Products/Combination Treatment Modalities 26 Discovery Products/Combination Treatment Modalities 27 Merck KGaA - Drug Profiles 28 cetuximab 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 avelumab 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 choriogonadotropin alfa 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 cladribine 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 atacicept 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 M-2736 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 pimasertib hydrochloride 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 sprifermin 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 tecemotide 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 tepotinib 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 BGB-283 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 BGB-290 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 DI-B4 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 L-Praziquantel 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 M-1095 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 M-2698 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 M-2951 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 M-3814 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 M-7824 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 M-9241 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 MSC-2015103B 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 pimasertib hydrochloride + voxtalisib 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 rimeporide 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 ALX-0751 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 AS-605240 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 cilengitide 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 DDD-498 74 Product Description 74 Mechanism of Action 74 R&D Progress 74 M-7583 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 Monoclonal Antibody Conjugates for Oncology 76 Product Description 76 Mechanism of Action 76 R&D Progress 76 Small Molecule to Inhibit Aurora B Kinase for Cancer 77 Product Description 77 Mechanism of Action 77 R&D Progress 77 Small Molecules to Inhibit CDK8 for Colorectal Carcinoma 78 Product Description 78 Mechanism of Action 78 R&D Progress 78 Vaccine 1 for Cancer 79 Product Description 79 Mechanism of Action 79 R&D Progress 79 Vaccine 2 for Cancer 80 Product Description 80 Mechanism of Action 80 R&D Progress 80 Small Molecule to Inhibit SYK for Inflammation 81 Product Description 81 Mechanism of Action 81 R&D Progress 81 Small Molecule to Inhibit WNT Pathway for Oncology 82 Product Description 82 Mechanism of Action 82 R&D Progress 82 Small Molecules for Autoimmune Disorder and Oncology 83 Product Description 83 Mechanism of Action 83 R&D Progress 83 Small Molecules for Multiple Sclerosis 84 Product Description 84 Mechanism of Action 84 R&D Progress 84 Small Molecules to Agonize TNFR for Cancer 85 Product Description 85 Mechanism of Action 85 R&D Progress 85 Merck KGaA - Pipeline Analysis 86 Merck KGaA - Pipeline Products by Target 86 Merck KGaA - Pipeline Products by Route of Administration 89 Merck KGaA - Pipeline Products by Molecule Type 90 Merck KGaA - Pipeline Products by Mechanism of Action 91 Merck KGaA - Recent Pipeline Updates 93 Merck KGaA - Dormant Projects 103 Merck KGaA - Discontinued Pipeline Products 105 Discontinued Pipeline Product Profiles 105 abituzumab 105 anastrozole 105 atacicept 106 cilengitide 106 cladribine 106 Drug to Antagonize Oxytocin Receptor for Pre-term Labor 106 EMD-1204831 106 emfilermin 106 EML-4156 106 M-1095 106 matuzumab 106 MSB-0010445 107 onercept 107 Osteopontin 107 pimasertib hydrochloride 107 plovamer acetate 107 sarizotan hydrochloride 107 tecemotide 107 tucotuzumab celmoleukin 108 Merck KGaA - Company Statement 109 Merck KGaA - Locations And Subsidiaries 112 Head Office 112 Other Locations & Subsidiaries 112 Appendix 122 Methodology 122 Coverage 122 Secondary Research 122 Primary Research 122 Expert Panel Validation 122 Contact Us 122 Disclaimer 123
List of Tables
Merck KGaA, Key Information 8 Merck KGaA, Key Facts 8 Merck KGaA - Pipeline by Indication, 2016 11 Merck KGaA - Pipeline by Stage of Development, 2016 14 Merck KGaA - Monotherapy Products in Pipeline, 2016 15 Merck KGaA - Combination Treatment Modalities in Pipeline, 2016 16 Merck KGaA - Partnered Products in Pipeline, 2016 17 Merck KGaA - Partnered Products/ Combination Treatment Modalities, 2016 18 Merck KGaA - Out-Licensed Products in Pipeline, 2016 20 Merck KGaA - Out-Licensed Products/ Combination Treatment Modalities, 2016 21 Merck KGaA - Filing rejected/Withdrawn, 2016 22 Merck KGaA - Phase III, 2016 23 Merck KGaA - Phase II, 2016 24 Merck KGaA - Phase I, 2016 25 Merck KGaA - Preclinical, 2016 26 Merck KGaA - Discovery, 2016 27 Merck KGaA - Pipeline by Target, 2016 86 Merck KGaA - Pipeline by Route of Administration, 2016 89 Merck KGaA - Pipeline by Molecule Type, 2016 90 Merck KGaA - Pipeline Products by Mechanism of Action, 2016 91 Merck KGaA - Recent Pipeline Updates, 2016 93 Merck KGaA - Dormant Developmental Projects,2016 103 Merck KGaA - Discontinued Pipeline Products, 2016 105 Merck KGaA, Subsidiaries 112
List of Figures
Merck KGaA - Pipeline by Top 10 Indication, 2016 10 Merck KGaA - Pipeline by Stage of Development, 2016 14 Merck KGaA - Monotherapy Products in Pipeline, 2016 15 Merck KGaA - Partnered Products in Pipeline, 2016 17 Merck KGaA - Out-Licensed Products in Pipeline, 2016 20 Merck KGaA - Pipeline by Top 10 Target, 2016 86 Merck KGaA - Pipeline by Route of Administration, 2016 89 Merck KGaA - Pipeline by Molecule Type, 2016 90 Merck KGaA - Pipeline Products by Top 10 Mechanism of Action, 2016 91
Global gold nanoparticles market size is expected to reach 4.99 billion by 2020, witnessing gains at a CAGR of 24.7%. Positive outlook towards the increasing applications of nanotechnology in medical and dentistry such as drug delivery systems, nanomRead More...
Global aquafeed market size is anticipated to be valued at USD 165.04 billion by 2022, as per a new research report by Radiant Insights, Inc. Increase in fish consumption for direct and indirect consumer applications is anticipated to drive the markeRead More...
Global Biocides market size is likely to be valued at USD 11.9 billion by 2022; as per a new research report by Radiant Insights, Inc. Growth in water treatment process units particularly in China, Japan and India is likely to drive demand. IncreasinRead More...
Global amino acids market size is anticipated to be valued at USD 35.4 billion by 2022, as per a new research report by Radiant Insights, Inc. Increase in animal feed additive demand owing to regulate metabolism in livestock production owing to growiRead More...
Global embedded system market is projected to be valued at USD 214.39 billion by 2020, as per a new research report by Radiant Insights, Inc. Rising demand from end-use industries such as automotive and healthcare coupled with emergence of Internet oRead More...
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.